Skin Delivery of Clec4a Small Hairpin RNA Elicited an Effective Antitumor Response by Enhancing CD8(+) Immunity In Vivo

doi:10.1016/j.omtn.2017.10.015

CNU IR > College of Smart Living > Dept. of Senior Service and Health Management > Periodical Articles > Item 310902800/31729

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31729

Title:	Skin Delivery of Clec4a Small Hairpin RNA Elicited an Effective Antitumor Response by Enhancing CD8(+) Immunity In Vivo
Authors:	Weng, Tzu-Yang Li, Chia-Jung Li, Chung-Yen Hung, Yu-Hsuan Yen, Meng-Chi Chang, Yu-Wei Chen, Yu-Hung Chen, Yi-Ling Hsu, Hui-Ping Chang, Jang-Yang Lai, Ming-Derg
Contributors:	Natl Cheng Kung Univ, Coll Med, Dept Biochem & Mol Biol Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci Kaohsiung Med Univ,Kaohsiung Med Univ Hosp, Dept Emergency Med Natl Cheng Kung Univ, Dept Med Chia Nan Univ Pharm & Sci, Dept Senior Citizen Serv Management Natl Cheng Kung Univ, Coll Med,Natl Cheng Kung Univ Hosp, Dept Surg Natl Hlth Res Inst, Natl Inst Canc Res
Keywords:	Human Dendritic Cells Cancer-Immunotherapy Lectin Receptors Dna Vaccine T-Cells Indoleamine 2,3-Dioxygenase Inhibitory Motif Dcir Antigen Immunoreceptor
Date:	2017-12-15
Issue Date:	2018-11-30 15:54:30 (UTC+8)
Publisher:	Cell Press
Abstract:	Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. The present study investigated whether downregulating the expression of Clec4a via skin delivery of small hairpin RNA (shRNA) using a gene gun produced stronger host immunity and inhibited tumor progression in animal models. Administration of Clec4a2 shRNA delayed tumor growth in both mouse bladder and lung tumor-bearing mouse models. The result was further confirmed with a compensation experiment showing that the antitumor effects induced by Clec4a2 shRNA were restored by co-injection of a plasmid expressing exogenous Clec4a2. Increased numbers of infiltrating CD4(+) and CD8(+) T cells at tumor sites were observed in mice treated with Clec4a2 shRNA. Splenocytes from mice with Clec4a2 shRNA administration exhibited stronger cytotoxic activity compared with splenocytes from control mice. CD8-deletion in vivo abrogated the antitumor effects elicited by Clec4a2 shRNA. Additionally, shClec4a enhanced the antitumor effects of the Neu DNA vaccine in the MBT-2 tumor model. In summary, the findings provide evidence that silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy.
Relation:	Molecular Therapy-Nucleic Acids, v.9, pp.419-427
Appears in Collections:	[Dept. of Senior Service and Health Management] Periodical Articles

Files in This Item:

File	Description	Size	Format
10.1016-j.omtn.2017.10.015.pdf		1788Kb	Adobe PDF	1	View/Open
index.html		0Kb	HTML	1176	View/Open

Loading...